AstraZeneca
1,782.00 SEK
-0.47 %
Less than 1K followers
AZN
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for AstraZeneca
P/E
Median 2019-2025
EV/S
Median 2019-2024
EV/EBIT
Median 2019-2024
Dividend yield
Median 2019-2025
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 940.20 | 828.40 | 1,062.80 | 1,403.50 | 1,353.50 | 1,446.50 | 1,703.50 |
| Shares | 1,301.0 | 1,312.0 | 1,496.0 | 1,548.0 | 1,549.1 | 1,550.5 | 1,550.9 |
| Market cap | 1,223,200.2 | 1,086,860.8 | 1,589,948.8 | 2,172,618.0 | 2,096,719.4 | 2,242,865.1 | 2,641,971.7 |
| Enterprise value | 1,334,526.3 | 1,186,261.5 | 1,810,164.1 | 2,413,327.9 | 2,328,524.3 | 2,516,469.0 | - |
| EV/S | 6.1 | 5.4 | 5.3 | 5.2 | 5.0 | 4.2 | - |
| EV/EBITDA | 21.3 | 17.4 | 26.4 | 25.0 | 17.0 | 13.7 | - |
| EV/EBIT | 48.8 | 28.0 | 189.3 | 61.6 | 28.2 | 22.8 | - |
| P/E | 98.0 | 41.4 | 1,567.2 | 63.4 | 34.9 | 28.9 | 28.1 |
| P/B | 8.96 | 8.47 | 4.47 | 5.62 | 5.31 | 4.98 | 5.90 |
| P/S | 5.6 | 5.0 | 4.7 | 4.7 | 4.5 | 3.8 | 4.9 |
| Dividend yield | 2.8 % | 1.8 % | 2.4 % | 2.2 % | 2.2 % | 2.4 % | 1.7 % |
| Equity ratio | 23.8 % | 23.4 % | 37.3 % | 38.4 % | 38.7 % | 39.3 % | 42.7 % |
| Gearing ratio | 124.9 % | 130.3 % | 74.7 % | 78.9 % | 73.6 % | 74.1 % | 60.8 % |